Abstract: The thienopyrimidines of the formula (I) and their physiologically compatible salts display a phosphodiesterase V inhibiting activity and can be used for treating diseases of the cardiovascular system and for treatment and/or therapy of erectile dysfunction.

Abstract: Thienopyrimidines of the formula I and their physiologically acceptable salts, in which R1, R2 and X have the meanings given in claim 1, inhibit phosphodiesterase V and can be employed for the treatment of illnesses of the cardiovascular system and for the treatment and/or therapy of impaired potency.

Abstract: The invention relates to monoreactive mesogenic compounds of formula I wherein P, Sp, X, n, Y1, Y2, r1, r2, r3, Z1 and Z2 are defined herein.

Abstract: A continuous process for the preparation of inorganic and organic bead polymers using a static micromixer is disclosed. The bead polymers obtainable by the process according to the invention have a very uniform particle size distribution, which can be set in a range of between 0.1 and 300 &mgr;m.

Abstract: The invention relates to a pearl luster pigment which may possess a first, inner layer, consisting of a platelet-shaped substrate, a second layer, comprising one or more metal oxides, the first and second layers forming a calcined base pigment, a third layer, comprising the corresponding uncalcined oxide, hydroxide or oxide hydrate of the oxide of the second layer, a fourth layer, comprising oxides, hydroxides and/or oxide hydrates of silicon or aluminum, a fifth layer, comprising oxides, hydroxides and/or oxide hydrates of silicon, aluminum, zirconium and/or cerium, this layer differing from the fourth layer, and a sixth layer, comprising one or more organofunctional coupling reagents. The present invention relates to also a preparation process, and the use of the pigments in paints, inks, plastics, coatings and cosmetics.

Abstract: Arylalkanoylpyridazine derivatives of the formula I and the physiologically acceptable salts thereof in which R1, R2, R3, R4, Q and B have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumors, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases and AIDS.

Abstract: Compounds of the formula I in which R1, R2 and R3 have the stated meanings, and their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be used for the treatment of thromboses, osteoporoses, oncoses, stroke, myocardial infarct, ischemias, inflammations, arteriosclerosis and osteolytic disorders.

Abstract: The invention relates to a method for disubstituting carboxylic acid amides on the geminal carbonyl-C-atom using at least one grignard reagent in the presence of a metal alcoholate compound used as a catalyst and in the presence of another organometallic compound used as a co-catalyst.

Abstract: The present invention relates to 2,6-di-tert-butylphenols of the formula I in which R, A1 A2, Z1, Z2 m and n are as defined herein, and their use as stabilizers or antioxidants.

Abstract: The invention relates to a method of preparing lithium complex salts and their intermediaries and to the use of these in electrolytes.

Abstract: Disclosed is a 2-phenyl-benzimidazolesulfonic acid according to the formula in which n is 0, 1 or 2 and m is 2 or 3, R1, R2, R3, R4 and R5, are each a radical such as H, C1-8-alkyl, C1-8-alkoxy, hydroxyl, sulfate, nitro, F, Cl, Br or I radicals, and R6 is a C1-8-alkyl or C1-8-alkoxy radical. This compound can be effectively used as a UV filter, and as part of a cosmetic formulation which comprise these compounds. A process for preparation of the compound is disclosed as well.

Abstract: A cosmetic preparation having butylmethoxydibenzoyhmethane as a protection filter and insoluble inorganic particles which are titanium dioxide particles doped with cerium or iron ions which absorb in the UVA region and are added to improve the photostability of the cosmetic preparation.

Abstract: Compounds are used as catalysts according to general formula (1) M+x(C(SO2CF3)3)x, whereby x is equal to 1 or 2; M represents one hydrogen or alkaline metal atom when x equals 1; and M represents one alkaline-earth metal atom when x equals 2. The invention also relates to a novel Mg compound of formula (1).

Abstract: The invention relates to a non-dusting, homogeneous pigment preparation which is distinguished by the fact that it comprises at least 40% by weight of one or more effect pigments and 0.5-59.5% by weight of a modified colophony resin, based on the pigment preparation, and the use thereof, in particular for the production of dry preparations. The pigment preparation according to the invention and the dry preparations produced therefrom are particularly suitable for the pigmenting of paints, coatings, powder coatings, printing inks and plastics.

Abstract: The invention relates to a process as described in claim of preparing a reflective film comprising a layer of a polymerized mesogenic material with helically twisted structure, wherein the helix axis is perpendicular to the film plane, and containing regions with varying helical pitch, to a reflective film obtainable by such a process, to the use of such a reflective film as reflective broadband or notch polarizer or as a multicoloured film or image in liquid crystal displays, as colour filter, in effect pigments, for decorative or security applications, and to a liquid crystal display comprising a liquid crystal cell and a reflective polarizer as described in the foregoing and the following, and optionally further comprising one or more compensaters or polarizers.

Abstract: The thienopyrimidines of the formula (I) and their physiologically compatible salts display a phosphodiesterase V inhibiting activity and can be used for treating diseases of the cardiovascular system and for treatment and/or therapy of erectile dysfunction.

Abstract: Arylalkanoylpyridazine derivatives of the formula I and their physiologically acceptable salts and solvates, in which R1, R2, Q and B have the meanings indicated in Claim 1, show an inhibition of phosphodiesterase IV and can be employed for the treatment of asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases, inflammatory diseases, autoimmune disorders, such as, for example, rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumor growth or tumor metastases, sepsis, memory disorders, atherosclerosis and AIDS.

Abstract: The invention relates to cholesteric polymer flakes obtainable from a chiral polymerizable mesogenic material, to methods of manufacturing such cholesteric flakes, to the use of certain chiral and achiral polymerizable compounds with one or more terminal polymerizable groups for the manufacturing of such flakes and to the use of such cholesteric flakes as effect pigments in spraying or printing inks or paints or colored plastics for different applications, especially for automotive use, cosmetic products and security applications.

Abstract: Surface-modified conductive pigment obtainable by partial coating of a conductive pigment with an organic modifying agent. The modifying agent is an organometallic compound of the elements silicon, tin, titanium, zirconium or aluminum. The pigment is prepared by dispersing a conductive pigment, subsequently adding the modifying agent, if appropriate as a mixture with a solvent, to the pigment dispersion, and in particular in an amount such that the powder electrical conductance of the partly coated conductive pigment is in the range between 80% of the starting value and 10−7 S, removing the solvent present, if appropriate, with further agitation and heating of the pigment to 100° C. and finally drying the partly coated pigment.

Abstract: The invention relates to a process for the preparation of organic methanide electrolytes in useable quality for use in electrochemical cells and batteries.